[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported equity awards and vesting terms. The Form 4 shows transactions dated 08/14/2025 with the filing signed on 08/18/2025. Non-derivative activity records an acquisition of 6,000 shares of common stock at $0, bringing Mr. Allan's direct beneficial ownership to 25,631 shares. Derivative activity shows grants of 12,000 performance stock units (PSUs) and an additional 6,000 PSUs under a modification code; each unit converts to one share of common stock on vesting. The award vests in two equal tranches: half on August 14, 2025 and half on August 14, 2026, subject to continued service and certification of performance criteria.

Positive

• Acquisition of 6,000 common shares reported, increasing direct beneficial ownership to 25,631 shares
• Grant of 12,000 performance stock units that convert one-for-one to common shares upon certification and vesting
• Clear vesting schedule: 50% vests on 08/14/2025 and 50% on 08/14/2026, conditioned on continued service

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider received equity awards that increase direct ownership and include performance-based units vesting over two years.

The Form 4 discloses an immediate increase of 6,000 common shares recorded at $0 and granted performance stock units totaling 18,000 units (12,000 reported as newly granted and 6,000 under modification). The PSUs convert one-for-one into common shares upon satisfaction of performance criteria and service-based vesting (50% on 08/14/2025; 50% on 08/14/2026). As General Counsel and a director, the reporting person’s compensation mix includes equity incentives that align management with shareholder outcomes. The filing contains no information on cash consideration, exercise prices for options, or changes to total outstanding share count.

Corporate Governance Expert

TL;DR: Compensation committee-certified PSUs indicate performance-linked pay with standard service-based vesting.

The disclosure specifies that the 12,000-unit award is conditioned on certification by the compensation committee, confirming these are performance-contingent restricted stock units. Vesting schedule and conversion ratio (one PSU equals one share) are explicitly stated. The Form 4 identifies the reporting person as both an officer and director, which is relevant for governance transparency. The filing does not include the specific performance targets or how these awards relate to peer or internal pay benchmarks.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		M		6,000	A	$0	25,631	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	08/14/2025		A(2)		12,000		(3)	08/14/2026	Common Stock	12,000	$0	12,000	D
Performance Stock Units	(1)	08/14/2025		M			6,000	(3)	08/14/2026	Common Stock	6,000	$0	6,000	D

Explanation of Responses:

1. Each performance stock unit represents a right to receive one share of the Issuer's common stock.

2. This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

3. Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

	/s/ Jonathan Allan	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Jonathan Allan report on Form 4 for STOK?

The Form 4 reports acquisition of 6,000 shares of common stock and grants/modifications of 18,000 performance stock units (12,000 granted, 6,000 modified) dated 08/14/2025.

How many shares does Jonathan Allan beneficially own after the reported transaction?

Following the reported transaction, Mr. Allan directly beneficially owns 25,631 shares of Stoke Therapeutics common stock.

What are the vesting terms for the performance stock units reported?

Each PSU converts to one share and vests in two equal tranches: half on 08/14/2025 and half on 08/14/2026, subject to continued service and performance certification.

Were any prices reported for the acquired securities?

The non-derivative acquisition of 6,000 common shares is reported at a price of $0; the PSUs are performance-based and reported with an underlying share conversion at $0 until vesting.

What is the reporting person's role at the company according to the filing?

The filing identifies Jonathan Allan as a Director and an Officer with the title General Counsel & Corporate Secretary.